anti par1  (Santa Cruz Biotechnology)

Journal: Frontiers in Molecular Biosciences

Article Title: The predictive role of protease-activated receptor (PAR-1) polymorphisms and activated microplatelets on the severity of atherosclerosis – preliminary studies

doi: 10.3389/fmolb.2025.1662954

Figure Lengend Snippet: The cytometric analysis (SSC and FCS) of isolated human resting platelets (A, D) , gated and labeled PAR-1 without activation (B, E) , and gated and labeled PAR-1 with activation by 10 µM TRAP (C, F) ; labeled with anti-CD61-FITC and PAR-1-APC antibodies (G–I) . The level of PAR-1 expression was read from gates P1. Markers M1 and M2 indicate the gates for microparticles and normal platelets, with the PAR-1 analysis applied to the summed population. An example image from a patient with DM is shown.

Article Snippet: Next: For the PAR-1 test without PLT activation, 5 μL of PAR-1-APC antibodies at a concentration of 5 μg/5 × 10 5 cells (Allophycocyanin (APC)-conjugated mouse monoclonal anti-human PAR-1; clone# 731115; mouse isotype: IgG1, R&D Systems, Minneapolis, Canada) and 5 μL of CD61-FITC antibodies (Monoclonal Mouse Anti-Human CD61, Platelet Glycoprotein IIIa/FITC, Clone Y2/51, code: F0803, DakoCytomation, Glostrup, Denmark) were added.

Techniques: Isolation, Labeling, Activation Assay, Expressing

Journal: Frontiers in Molecular Biosciences

Article Title: The predictive role of protease-activated receptor (PAR-1) polymorphisms and activated microplatelets on the severity of atherosclerosis – preliminary studies

doi: 10.3389/fmolb.2025.1662954

Figure Lengend Snippet: The percentage of PAR-1 receptor expression before and after the addition of the thrombin receptor activating peptide (TRAP) in blood samples from patients with diabetic macroangiopathy (DM), the control group (CONTROL), and atherosclerosis obliterans (AO).

Article Snippet: Next: For the PAR-1 test without PLT activation, 5 μL of PAR-1-APC antibodies at a concentration of 5 μg/5 × 10 5 cells (Allophycocyanin (APC)-conjugated mouse monoclonal anti-human PAR-1; clone# 731115; mouse isotype: IgG1, R&D Systems, Minneapolis, Canada) and 5 μL of CD61-FITC antibodies (Monoclonal Mouse Anti-Human CD61, Platelet Glycoprotein IIIa/FITC, Clone Y2/51, code: F0803, DakoCytomation, Glostrup, Denmark) were added.

Techniques: Expressing, Control

Journal: Frontiers in Molecular Biosciences

Article Title: The predictive role of protease-activated receptor (PAR-1) polymorphisms and activated microplatelets on the severity of atherosclerosis – preliminary studies

doi: 10.3389/fmolb.2025.1662954

Figure Lengend Snippet: (A) Separation of DNA molecules in a 3% agarose gel of PAR-1 gene amplification products with the −506 I/D polymorphism. Lanes: 1 – homozygous I/I, 2 – heterozygous I/D, 3 – homozygous D/D, M–GeneRuler™ 50bp DNA Ladder (Fermentas). (B) The percentage distribution of the −506 I/D polymorphism variants in the PAR-1 gene: homozygous D/D (blue), heterozygous I/D (red), and homozygous I/I (green).

Article Snippet: Next: For the PAR-1 test without PLT activation, 5 μL of PAR-1-APC antibodies at a concentration of 5 μg/5 × 10 5 cells (Allophycocyanin (APC)-conjugated mouse monoclonal anti-human PAR-1; clone# 731115; mouse isotype: IgG1, R&D Systems, Minneapolis, Canada) and 5 μL of CD61-FITC antibodies (Monoclonal Mouse Anti-Human CD61, Platelet Glycoprotein IIIa/FITC, Clone Y2/51, code: F0803, DakoCytomation, Glostrup, Denmark) were added.

Techniques: Agarose Gel Electrophoresis, Amplification

Journal: Frontiers in Molecular Biosciences

Article Title: The predictive role of protease-activated receptor (PAR-1) polymorphisms and activated microplatelets on the severity of atherosclerosis – preliminary studies

doi: 10.3389/fmolb.2025.1662954

Figure Lengend Snippet: (A) The result of the restriction digestion of PCR products with the MvaI enzyme to check for the presence of the −1426 C/T polymorphism in the PAR-1 gene. Lanes: 1 – 6 homozygotes C/C, M–GeneRuler™ 100bp DNA Ladder (Fermentas). (B) The percentage distribution of the variants of the −1426 C/T polymorphism in the PAR-1 gene: homozygote C/C (blue color), heterozygote C/T (red color), homozygote T/T (green color).

Article Snippet: Next: For the PAR-1 test without PLT activation, 5 μL of PAR-1-APC antibodies at a concentration of 5 μg/5 × 10 5 cells (Allophycocyanin (APC)-conjugated mouse monoclonal anti-human PAR-1; clone# 731115; mouse isotype: IgG1, R&D Systems, Minneapolis, Canada) and 5 μL of CD61-FITC antibodies (Monoclonal Mouse Anti-Human CD61, Platelet Glycoprotein IIIa/FITC, Clone Y2/51, code: F0803, DakoCytomation, Glostrup, Denmark) were added.

Techniques:

Journal: Frontiers in Molecular Biosciences

Article Title: The predictive role of protease-activated receptor (PAR-1) polymorphisms and activated microplatelets on the severity of atherosclerosis – preliminary studies

doi: 10.3389/fmolb.2025.1662954

Figure Lengend Snippet: (A) Example separations of amplification products of the DNA fragment encompassing the IVSn-14 A/T polymorphism site of the PAR-1 gene using the SNaPshot method. Alleles were determined based on the size of primers and the colors of fluorescently labeled ddNTPs (terminators) incorporated during the primer extension reaction. (A) red peak, wild-type homozygote (AA); (B) green and red peaks, heterozygote (AT); (C) green peak, mutated homozygote (TT). (B) The percentage distribution of the variants of the IVS-14 A/T polymorphism of the PAR-1 gene is as follows: homozygote A/A (blue color), heterozygote A/T (red color), and homozygote T/T (green color).

Article Snippet: Next: For the PAR-1 test without PLT activation, 5 μL of PAR-1-APC antibodies at a concentration of 5 μg/5 × 10 5 cells (Allophycocyanin (APC)-conjugated mouse monoclonal anti-human PAR-1; clone# 731115; mouse isotype: IgG1, R&D Systems, Minneapolis, Canada) and 5 μL of CD61-FITC antibodies (Monoclonal Mouse Anti-Human CD61, Platelet Glycoprotein IIIa/FITC, Clone Y2/51, code: F0803, DakoCytomation, Glostrup, Denmark) were added.

Techniques: Amplification, Labeling

Journal: Frontiers in Molecular Biosciences

Article Title: The predictive role of protease-activated receptor (PAR-1) polymorphisms and activated microplatelets on the severity of atherosclerosis – preliminary studies

doi: 10.3389/fmolb.2025.1662954

Figure Lengend Snippet: Multivariate analysis: (A–D) Number of microparticles with PAR-1+TRAP; (E–F) Number of microparticles with BMI (Figure 4.12E-F) and age with smoking.

Article Snippet: Next: For the PAR-1 test without PLT activation, 5 μL of PAR-1-APC antibodies at a concentration of 5 μg/5 × 10 5 cells (Allophycocyanin (APC)-conjugated mouse monoclonal anti-human PAR-1; clone# 731115; mouse isotype: IgG1, R&D Systems, Minneapolis, Canada) and 5 μL of CD61-FITC antibodies (Monoclonal Mouse Anti-Human CD61, Platelet Glycoprotein IIIa/FITC, Clone Y2/51, code: F0803, DakoCytomation, Glostrup, Denmark) were added.

Techniques:

Journal: Frontiers in Oncology

Article Title: Significance of FXa and its receptor PAR2 for the growth of colon cancer cells in vitro and in vivo

doi: 10.3389/fonc.2025.1631350

Figure Lengend Snippet: Key figures of the animal study. Trial days. (A) Shown is the number of days the animals were subjected to the study, with a maximum of 21 days. PAR2-KO (black) mice stayed significantly longer in the trial than WT (white) mice. This finding is applicable to all three treatment groups. The animals were administered either 5 mg/kg or 50 mg/kg body weight Apixaban plus vehicle or vehicle only (control). Tumor size. (B) Additionally, PAR2-KO mice exhibited a significantly reduced tumor size when compared to their WT counterparts. Ratio of spleen weight to body weight. (C) Macroscopic discrepancies between the animal strains were observed in the ratio of spleen weight to body weight. Compared to WT (white) animals, PAR2-KO (black) animals showed a significantly higher spleen weight in relation to body weight. Apixaban concentration. (D) Apixaban plasma concentrations measured by UPLC-MS/MS in WT (white) and PAR2-KO mice (black) treated with 50 mg/kg or w/o (control) Apixaban. (E) Significantly higher Apixaban levels could also be detected in the tumors of treated animals. PCR analyzes. (F) Apixaban is metabolized via CYP3A4. The murine counterpart is CYP3A11. PCR analyses show that the treatment of the animals with Apixaban significantly increases the expression of CYP3A11 in the liver at RNA level in both, WT (white) and PAR2-KO mice (black). Further Specific RNA analyses of the removed spleens demonstrate elevated expression levels of the following genes in PAR2-KO mice: MMP2 (G) , MMP9 (H) , COX2 (I) , PAR1 (J) , EGFR (L) . PAR2 can only be detected in WT mice (K) . N = 3-6 (I-VI), Shown is the relative expression of the target normalized to Gapdh and relative to the control approaches. Mean ± SD of n independent experiments is presented for all data. One-way ANOVA, Dunnett posthoc test, p < 0.05 (*).

Article Snippet: After blocking [Li-cor, Cat. #927-60001], membranes were incubated overnight at 4°C under rotating conditions with the following primary antibodies: AKT (1:1000) [Cell Signaling, Cat. #4691], phospho-AKT (1:1000) [Cell Signaling, Cat. #4060], p38 (1:500) [Cell Signaling, Cat. #8690], phospho-p38 (1:500) [Cell Signaling, Cat. #4511], p44/42 (1:1000) [Cell Signaling, Cat. #4695], phospho-p44/42 (1:1000) [Cell Signaling, Cat. #4370], PAR2 (1:200) [Santa Cruz Biotechnologies, Cat. #sc-13504], PAR1 (1:200) [Santa Cruz Biotechnologies, Cat. #13503].

Techniques: Control, Concentration Assay, Clinical Proteomics, Tandem Mass Spectroscopy, Expressing